Clinical Trials

29 enrolled

Carcinoma, Hepatocellular

NCT07501169 2026-04-13

STAR-01

33 enrolled

Small Cell Lung Carcinoma

NCT07470840 2026-03-24

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

27 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07489300 2026-03-24

BACON

40 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07193186 2026-02-27

Anlotinib and Benmelstobart in DTC

23 enrolled

Head & Neck

Thyroid Neoplasms

NCT07388875 2026-02-05

SKB264-ANLO

Small Cell Lung Carcinoma

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT07363512 2026-01-23

Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus

27 enrolled

Carcinoma, Hepatocellular

NCT07358676 2026-01-22

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Carcinoma

NCT07307443 2025-12-29

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

28 enrolled

Lung Neoplasms

NCT07294261 2025-12-19

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07205185 2025-10-03

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

46 enrolled

Sarcoma

NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

165 enrolled

Extensive Stage Lung Small Cell Cancer

NCT07128693 2025-08-19

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT06977828 2025-06-29

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07022301 2025-06-15

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

Small Cell Lung Cancer Extensive Stage

NCT06978153 2025-05-18

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer

66 enrolled

Limited Stage Small Cell Lung Cancer

NCT06429397 2025-04-29

Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma

22 enrolled

Endocrine

Pheochromocytoma

NCT06851169 2025-02-28

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response

58 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06761417 2025-01-08

A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults

49 enrolled

Other solid neoplasm

Solid Tumors

NCT06699498 2024-11-21

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

45 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06634667 2024-10-10

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Carcinoma, Non-Small-Cell Lung

NCT06621095 2024-10-01

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

104 enrolled

Pancreatic Neoplasms

NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

40 enrolled

Breast

Breast Neoplasms

NCT06483672 2024-07-03

LungBrain001

27 enrolled

CNSThoracic

Adenocarcinoma of Lung, Brain Neoplasms

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

178 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06426797 2024-05-23

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

NCT06327698 2024-03-25

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Dermatologic

Melanoma

NCT06221462 2024-01-25

PRIORITY

Carcinoma, Non-Small-Cell Lung

NCT06222944 2024-01-25

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

90 enrolled

Stomach Neoplasms

NCT06182761 2023-12-27

WUKONG-9

45 enrolled

NSCLC

NCT05996484 2023-08-21

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Esophageal Neoplasms

NCT05778149 2023-03-21

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

47 enrolled

Aumolertinib

NCT05550558 2022-09-28

CAN-RESPOND